Insomnia News and Research

Latest Insomnia News and Research

Study outlines agenda to help direct future caffeine dependence research

"I'm a zombie without my morning coffee." "My blood type is Diet Coke." "Caffeine isn't a drug, it's a vitamin." Most people make jokes like these about needing a daily boost from their favorite caffeinated beverage-whether first thing in the morning or to prevent the after-lunch slump.

29 Jan 2014

Study: Nightmares have greater emotional impact than bad dreams do

According to a new study by researchers at the University of Montreal, nightmares have greater emotional impact than bad dreams do, and fear is not always a factor. In fact, it is mostly absent in bad dreams and in a third of nightmares.

28 Jan 2014

Acute to chronic insomnia transition warns of depression risk

In patients with acute insomnia, long periods of light sleep may be the key driver to chronic insomnia and depression, research suggests.

27 Jan 2014

Prostate cancer patients treated with ADT experience mental, emotional well-being during treatment

A new study published in the Journal of Urology- reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life two years after treatment.

24 Jan 2014

Proper good night's sleep promotes both mental and physical health

Getting a good night's sleep means more than you probably think. "I would say the importance of sleep is definitely underestimated by the general public," said Dr. Sandhya Kumar, assistant professor of neurology at Wake Forest Baptist Medical Center and medical director of its Sleep Center.

23 Jan 2014

Targeting symptoms, rather than disorders, might help reduce work impact of mental health issues

Symptoms such as insomnia and emotional distress account for much of the work impact of mental health problems such as depression and anxiety, reports a study in the February issue of Medical Care.

23 Jan 2014

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.

21 Jan 2014

Technology increases cognitive behavioral therapy options for insomnia

Web- and telehealth-based delivery of cognitive behavioral therapy is effective for treating chronic insomnia, giving rural-dwelling adults more choice and better access to services, researchers report.

20 Jan 2014

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)).

18 Jan 2014

Persistent insomnia symptom risk high

Insomnia symptoms are often persistent, report researchers who found that targeting sleep-interfering behaviors may be one method of prevention.

13 Jan 2014

Merck announces FDA approval of ISENTRESS for oral suspension

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older.

9 Jan 2014

Support for DSM-5 mixed features specifier

Study findings uphold the value of the DSM-5 mixed features specifier of at least three depressive symptoms during a manic episode for diagnosing and classifying patients with mixed mania.

8 Jan 2014

Research: Daily meditation may improve symptoms of anxiety and depression

Some 30 minutes of meditation daily may improve symptoms of anxiety and depression, a new Johns Hopkins analysis of previously published research suggests.

7 Jan 2014

Sleep duration predicts chronic depression and anxiety

Short and long sleep duration, but not insomnia, predict a chronic course of depressive and anxiety disorders independent of symptom severity, research indicates.

6 Jan 2014

Japanese FIRST tool assesses vulnerability to insomnia

The Japanese version of the Ford Insomnia Response to Stress Test has been validated and confirmed as a reliable tool for assessing vulnerability to insomnia in healthy individuals.

24 Dec 2013

St. Louis College of Pharmacy's Amy Tiemeier suggests four easy resolutions for a healthier 2014

With the new year quickly approaching, many are beginning to think about resolutions. Amy Tiemeier, Pharm.D., BCPS, associate professor of pharmacy practice at St. Louis College of Pharmacy suggests four easy resolutions for a healthier 2014.

18 Dec 2013

Toddlers’ bedtime resistance may contribute to sleep problems

The bedtime you select for your toddler may be out of sync with his or her internal body clock, which can contribute to difficulties for youngsters attempting to settle in for the night, according to a new University of Colorado Boulder study.

17 Dec 2013

Insomnia impact on sleepiness and vigilance performance differs by age

Insomnia may affect people in different ways as they age, results of a prospective, 10-year study suggest.

16 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

13 Dec 2013